Who Qualifies for a GLP-1 Prescription? BMI, Conditions & Criteria
Modern Weight Science Editorial Team
Editorial Team
The eligibility criteria for a GLP-1 prescription depend on which drug, which indication, and whether you're going through insurance or paying out of pocket. Here's exactly what you need to know.
One of the first questions people ask is whether they qualify for a GLP-1 prescription. The answer depends on three things: the specific drug, the indication it's being prescribed for, and whether you're using insurance or paying cash through a telehealth provider.
FDA-approved criteria for weight management
Wegovy (semaglutide) and Zepbound (tirzepatide) are the two drugs specifically approved for chronic weight management in the US. The FDA criteria for both are:
- BMI of 30 or higher, OR
- BMI of 27 or higher plus at least one weight-related health condition
Weight-related conditions that satisfy the second criteria include type 2 diabetes, high blood pressure, high cholesterol, obstructive sleep apnea, and cardiovascular disease — among others. Your prescriber makes the final determination.
FDA-approved criteria for type 2 diabetes
Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes management. If you have type 2 diabetes, BMI thresholds are less relevant — the indication is the diagnosis itself. These drugs are often prescribed when lifestyle changes and metformin haven't achieved adequate blood sugar control.
Off-label prescribing
Physicians can prescribe any drug off-label for indications not listed in the FDA approval. In practice, some prescribers will prescribe diabetes-approved formulations (Ozempic, Mounjaro) for weight management in patients who meet the spirit of the clinical criteria but don't have a diabetes diagnosis. Off-label prescribing is legal and common — but insurance almost never covers it.
Telehealth providers and cash pay
Telehealth platforms that prescribe compounded or brand GLP-1s for cash often apply similar criteria to the FDA thresholds, but some are more flexible. Expect to complete a medical intake form covering your weight, BMI, health history, medications, and any contraindications. A clinician reviews this and makes the prescribing decision. You typically do not need an in-person visit.
Who cannot take GLP-1 medications
Key contraindications include:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
- Pregnancy or planning to become pregnant
- Severe gastrointestinal disease (e.g. gastroparesis)
- History of pancreatitis (requires careful evaluation)
- Serious hypersensitivity to the drug or its components
Your prescriber will screen for these. Be thorough and accurate in your intake history — these contraindications exist for real reasons.
What documentation you may need
For insurance-covered prescriptions, expect to provide: recent lab work, a documented weight history, prior treatment attempts (diet, exercise, sometimes prior medications), and evidence of qualifying conditions. Prior authorization processes vary significantly by insurer.
Qualification criteria are guidelines — your prescriber applies clinical judgment to your specific situation. This is educational content, not a determination of your eligibility.
About the author
Modern Weight Science Editorial Team
Editorial Team
Evidence-based research and educational content focused on metabolism, appetite regulation, and sustainable weight management. Our team synthesizes peer-reviewed research into clear, accessible guidance for informed health decisions.
Content reviewed against peer-reviewed research. Read our editorial policy →
Last updated May 2026
Frequently Asked Questions
Why do most diets fail long-term?
After diet-induced weight loss, the body mounts a sustained compensatory response: ghrelin stays elevated, leptin stays suppressed, resting metabolic rate decreases beyond mass loss, and NEAT drops automatically. The Biggest Loser follow-up study found contestants' metabolic rates remained ~500 kcal/day below prediction six years later, even as most regained significant weight. These changes work against maintenance regardless of effort.
How much weight loss is realistic on GLP-1 medications?
STEP 1 (semaglutide 2.4mg) showed 14.9% average weight loss at 68 weeks. SURMOUNT-1 (tirzepatide 15mg) showed 20.9% at 72 weeks — the highest ever recorded in a randomized pharmaceutical trial. These are means: approximately 30% of semaglutide users and 57% of high-dose tirzepatide users achieve ≥20% weight loss. Around 5-10% are non-responders.
Are GLP-1 medications more effective than diet and exercise alone?
Substantially more effective. In the STEP trials, semaglutide plus lifestyle counseling produced 14.9% weight loss versus 2.4% for lifestyle counseling alone — approximately a 6-fold difference. The key mechanism is that GLP-1 medications reduce the biological drive to eat, making caloric deficit sustainable rather than requiring constant active resistance against elevated hunger hormones.
What does long-term sustainable weight management look like?
National Weight Control Registry data from people who maintained ≥30 lbs weight loss for ≥1 year identifies consistent patterns: ~1 hour/day of physical activity, regular self-monitoring, consistent dietary patterns (including regular breakfast), and high dietary vigilance. With continued GLP-1 medication, two-year data shows ~15% weight loss maintained without significant rebound — suggesting pharmacological support may be part of a realistic long-term strategy for many people.
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.
Treatment Options
Clinically supervised approaches to metabolic health and weight management, evaluated by licensed physicians.
Ro Body
A physician-led telehealth program that evaluates your metabolic health and discusses FDA-cleared medication options where clinically appropriate.
Learn moreFound
Combines medical evaluation, pharmacotherapy when indicated, and behavioral coaching into a structured, ongoing metabolic health plan.
Learn moreCalibrate
A year-long metabolic reset built around GLP-1 medication, with physician oversight, registered dietitian support, and behavioral coaching.
Learn moreAffiliate disclosure: Modern Weight Science may earn a commission if you visit or purchase through these links, at no additional cost to you. Programs are listed for educational relevance. This is not a clinical recommendation — always consult a licensed healthcare professional before starting any treatment.
Weekly Digest
Get Evidence-Based Metabolic Health Insights Weekly
Research-backed insights on metabolism, GLP-1 science, and sustainable weight management — once a week.
Continue reading
Related articles
Set Point Theory: Does Your Body Have a Defended Weight?
The phrase "set point" is technically imprecise — researchers prefer "defended range" — but the underlying observation is well-supported. Across fifty years of starvation studies, twin research, and modern hormonal trials, bodies push back when their weight is moved.
Yo-Yo Dieting (Weight Cycling): Health Risks and How to Break the Cycle
Repeated cycles of loss and regain are independently associated with visceral fat redistribution, higher cardiovascular risk, and metabolic dysregulation — beyond the effects of obesity itself. The data make a quiet case for sustained treatment over repeated attempts.
Weight Regain After Stopping Ozempic: What the Research Actually Shows
STEP 4 randomised people who had already lost weight on semaglutide to either continue or switch to placebo. The placebo group regained two-thirds of their loss within a year — and the biology behind that pattern explains the rest.
Keto, Paleo, Intermittent Fasting — Why Popular Diets Don't Last
DIETFITS, A TO Z, PREDIMED. Long-term head-to-head diet trials reveal a stubborn pattern: at 12 months, the differences between approaches are smaller than the differences between adherent and non-adherent individuals.